UNITY appoints Bausch + Lomb R&D chief Yehia Hashad to board; advances UBX1325

Unity Biotechnology, Inc.

Dr. Yehia Hashad, EVP R&D and CMO at Bausch + Lomb, joins board effective March 8, 2025.
Hashad also appointed to Science Committee; receives 20,000-share option grant (3-yr vest) + $45k annual cash retainer.
CEO cites Hashad's expertise as UNITY prepares for Phase 2b ASPIRE 24-week data readout for UBX1325 in DME.
Hashad brings 25+ years in ophthalmology and retinal drug development, including leadership at Allergan and Novartis.
Board chairman notes Hashad's strategic perspective will help advance UBX1325 and pipeline.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Yehia Hashad

Director

Unity Biotechnology, Inc.

Effective: 2025-03-08
Filed: March 10, 2025, 7:59 PM ET

On March 8, 2025, the Board of Directors (the “Board”) of UNITY Biotechnology, Inc. (“Unity” or the “Company”) appointed Dr. Yehia Hashad, M.D., current executive vice president of research & development and chief medical officer at Bausch + Lomb, to the Board and as a member of the Science Committee, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Yehia Hashad was appointed as Director at Unity Biotechnology, Inc..

Action: appointed
Role: Director

Exact text from the filing

On March 8, 2025, the Board of Directors (the “Board”) of UNITY Biotechnology, Inc. (“Unity” or the “Company”) appointed Dr. Yehia Hashad, M.D., current executive vice president of research & development and chief medical officer at Bausch + Lomb, to the Board and as a member of the Science Committee, effective immediately.

View on SEC.gov

Source: SEC EDGAR

accession 0000950170-25-035924

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.